&nbsp;

Jul 2025

Regimen

ABIRPRED

Cancer Type:

Genitourinary,

Prostate

Intent: Adjuvant, Curative

Funding:

ODB - General Benefit

abiraterone

ODB - General Benefit

prednisone

Drugs Used:

abiraterone,

prednisone

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

LAZE+AMIV

Cancer Type:

Lung,

Non-Small Cell

Intent: Palliative

Drugs Used:

amivantamab (Unfunded),

lazertinib (Unfunded)

Quick Link(s):

Regimen Monograph

Jul 2025

Regimen

AZCTIVOS

Cancer Type:

Hematologic,

Leukemia - Acute Myeloid (AML)

Intent: Curative

Funding:

New Drug Funding Program

Azacitidine in combination with Ivosidenib (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Exceptional Access Program

Ivosidenib in combination with Azacitidine (Outpatient) - Previously Untreated Acute Myeloid Leukemia

Drugs Used:

ivosidenib,

azaCITIDine

Quick Link(s):

Regimen Monograph

Sep 2025

Drug

larotrectinib

Other Name(s): Vitrakvi®

Quick Link(s):

Sep 2025

Drug

luspatercept

Other Name(s): Reblozyl®

Quick Link(s):

Jul 2025

Drug

letrozole

Other Name(s): Femara®

Quick Link(s):

Nov 2020

Drug

lapatinib

Other Name(s): Tykerb®

Quick Link(s):

Jul 2025

Drug

arsenic trioxide

Other Name(s): Trisenox®

Quick Link(s):

Updated

Oct 2025

Guidelines and Advice

An Endorsement of the ASCO-SNO Guideline on Therapy for Diffuse Astrocytic and Oligodendroglial Tumors in Adults

Status: Current
ID: GL END 9-10
Version: 2

Dec 1969

Drug

abemaciclib

Other Name(s): Verzenio®

Quick Link(s):

Updated

Oct 2025

Regimen

ABEM

Cancer Type:

Breast

Intent: Palliative

Drugs Used:

abemaciclib (Unfunded)